Pfizer Inc. (PFE) is Howe & Rusling Inc.’s 4th Largest Position
Howe & Rusling Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 0.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 367,452 shares of the biopharmaceutical company’s stock after selling 2,476 shares during the period. Pfizer accounts for about 2.4% of Howe & Rusling Inc.’s holdings, making the stock its 4th biggest position. Howe & Rusling Inc.’s holdings in Pfizer were worth $13,118,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Northstar Group Inc. grew its stake in Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 35 shares in the last quarter. Peregrine Asset Advisers Inc. grew its stake in Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC grew its stake in Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 50 shares in the last quarter. River Wealth Advisors LLC grew its stake in Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC grew its stake in Pfizer by 0.5% during the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 69.75% of the company’s stock.
Several equities analysts recently commented on PFE shares. Jefferies Group set a $35.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Thursday, August 24th. BMO Capital Markets reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pfizer in a research note on Wednesday, September 6th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a research note on Wednesday, September 13th. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, September 19th. Finally, Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Buy” and a consensus target price of $38.77.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 earnings per share. equities research analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.68%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s payout ratio is presently 79.01%.
Pfizer announced that its Board of Directors has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,800 shares of company stock valued at $1,327,248. Company insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/pfizer-inc-pfe-is-howe-rusling-inc-s-4th-largest-position/1774001.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.